Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease
18/11/2025 12:14
Nov 18 (Reuters) - HLS Therapeutics Inc HLS.TO : HLS THERAPEUTICS ANNOUNCES HEALTH CANADA APPROVAL OF NILEMDO® FOR THE REDUCTION OF LDL-CHOLESTEROL IN CANADIANS AT RISK OF CARDIOVASCULAR DISEASE HLS THERAPEUTICS INC - COMMERCIAL LAUNCH EXPECTED IN Q2 2026 Source text: nCNWJ9L6Xa Further company coverage: HLS.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsBrief: Hls Therapeutics Increases Normal Course Issuer Bid
Brief: HLS Therapeutics Announces Q2 2026 Financial Results
Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
Canada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group